Tanshinones inhibit amyloid aggregation by amyloid-β peptide, disaggregate amyloid fibrils, and protect cultured cells

ACS Chemical Neuroscience

Volumn 4, Issue 6, 2013, Pages 1004-1015

  Wang, Qiuming ^a   Yu, Xiang ^a   Patal, Kunal ^a   Hu, Rundong ^a   Chuang, Steven ^a   Zhang, Ge ^a   Zheng, Jie ^a  

^a The University of Akron   (United States)

Author keywords

A ; Alzheimer's disease; amyloid; tanshinone

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; TANSHINONE I; TANSHINONE IIA; THIOFLAVINE; ABIETANE DERIVATIVE; AMYLOID BETA-PROTEIN (1-42); HERBACEOUS AGENT; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT; PROTEIN BINDING; TANSHINONE;

ARTICLE; ATOMIC FORCE MICROSCOPY; BETA SHEET; CARBOXY TERMINAL SEQUENCE; CELL ASSAY; CELL PROTECTION; CELL VIABILITY; CHINESE HERB; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING SITE; DRUG INHIBITION; DRUG ISOLATION; DRUG PROTEIN BINDING; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYDROPHOBICITY; IN VITRO STUDY; MOLECULAR DYNAMICS; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; SALVIA MILTIORRHIZA; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

SALVIA MILTIORRHIZA;

AMYLOID; AMYLOID BETA-PEPTIDES; CELL LINE, TUMOR; CELLS, CULTURED; DITERPENES, ABIETANE; DRUGS, CHINESE HERBAL; HUMANS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PROTEIN BINDING;

EID: 84879744934     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn400051e     Document Type: Article

References (71)

1. Brookmeyer, R., Johnson, E., Ziegler-Graham, K., and Arrighi, H. M. (2007) Forecasting the global burden of Alzheimer's disease Alzheimer's Dementia 3, 186-191
2. Sato, T., Kienlen-Campard, P., Ahmed, M., Liu, W., Li, H., Elliott, J. I., Aimoto, S., Constantinescu, S. N., Octave, J. N., and Smith, S. O. (2006) Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42 Biochemistry 45, 5503-5516
3. Glabe, C. C. (2005) Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta Subcell. Biochem. 38, 167-177
4. Hardy, J. and Selkoe, D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297, 353-356
5. Bloom, G. S., Ren, K., and Glabe, C. G. (2005) Cultured cell and transgenic mouse models for tau pathology linked to beta-amyloid Biochim. Biophys. Acta 1739, 116-124
6. Dash, P. K., Moore, A. N., and Orsi, S. A. (2005) Blockade of [gamma]-secretase activity within the hippocampus enhances long-term memory Biochem. Biophys. Res. Commun. 338, 777-782
7. Asai, M., Hattori, C., Iwata, N., Saido, T. C., Sasagawa, N., Szabó, B., Hashimoto, Y., Maruyama, K., Tanuma, S.-i., Kiso, Y., and Ishiura, S. (2006) The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice J. Neurochemistry 96, 533-540
8. Bacskai, B. J., Kajdasz, S. T., Christie, R. H., Carter, C., Games, D., Seubert, P., Schenk, D., and Hyman, B. T. (2001) Imaging of amyloid-[beta] deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy Nat. Med. 7, 369-372
9. Härd, T. and Lendel, C. (2012) Inhibition of amyloid formation J. Mol. Biol. 421, 441-465
10. Butterfield, S., Hejjaoui, M., Fauvet, B., Awad, L., and Lashuel, H. A. (2012) Chemical strategies for controlling protein folding and elucidating the molecular mechanisms of amyloid formation and toxicity J. Mol. Biol. 421, 204-236
11. Hilbich, C., Kisterswoike, B., Reed, J., Masters, C. L., and Beyreuther, K. (1992) Substitutions of Hydrophobic Amino-Acids Reduce the Amyloidogenicity of Alzheimers-Disease Beta-A4 Peptides J. Mol. Biol. 228, 460-473
12. Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., and Ashe, K. H. (2005) Natural oligomers of the amyloid-[beta] protein specifically disrupt cognitive function Nat. Neurosci. 8, 79-84
13. Findeis, M. A. (2000) Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization Biochim. Biophys. Acta, Mol. Basis Dis. 1502, 76-84
14. Soto, C., Sigurdsson, E. M., Morelli, L., Kumar, R. A., Castaño, E. M., and Frangione, B. (1998) Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy Nat. Med. 4, 822-826
15. Zhang, G., Leibowitz, M. J., Sinko, P. J., and Stein, S. (2003) Multiple-peptide conjugates for binding beta-amyloid plaques of Alzheimer's disease Bioconjugate Chem. 14, 86-92
16. Pai, A. S., Rubinstein, I., and Onyuksel, H. (2006) PEGylated phospholipid nanomicelles interact with beta-amyloid((1-42)) and mitigate its beta-sheet formation, aggregation and neurotoxicity in vitro Peptides 27, 2858-2866
17. Cabaleiro-Lago, C., Quinlan-Pluck, F., Lynch, I., Lindman, S., Minogue, A. M., Thulin, E., Walsh, D. M., Dawson, K. A., and Linse, S. (2008) Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles J. Am. Chem. Soc. 130, 15437-15443
18. Yoo, S. I., Yang, M., Brender, J. R., Subramanian, V., Sun, K., Joo, N. E., Jeong, S. H., Ramamoorthy, A., and Kotov, N. A. (2011) Inhibition of Amyloid Peptide Fibrillation by Inorganic Nanoparticles: Functional Similarities with Proteins Angew. Chem., Int. Ed. 50, 5110-5115
19. Kim, J. E. and Lee, M. (2003) Fullerene inhibits beta-amyloid peptide aggregation Biochem. Biophys. Res. Commun. 303, 576-579
20. Jameson, L. P., Smith, N. W., and Dzyuba, S. V. (2012) Dye-binding assays for evaluation of the effects of small molecule inhibitors on amyloid (Aβ) self-assembly ACS Chem. Neurosci. 3, 807-819
21. Masuda, M., Suzuki, N., Taniguchi, S., Oikawa, T., Nonaka, T., Iwatsubo, T., Hisanaga, S.-i., Goedert, M., and Hasegawa, M. (2006) Small molecule inhibitors of α-synuclein filament assembly Biochemistry 45, 6085-6094
22. Grelle, G., Otto, A., Lorenz, M., Frank, R. F., Wanker, E. E., and Bieschke, J. (2011) Black tea theaflavins inhibit formation of toxic amyloid-β and α-synuclein fibrils Biochemistry 50, 10624-10636
23. Cao, P. and Raleigh, D. P. (2012) Analysis of the inhibition and remodeling of islet amyloid polypeptide amyloid fibers by flavanols Biochemistry 51, 2670-2683
24. Cheng, B., Liu, X., Gong, H., Huang, L., Chen, H., Zhang, X., Li, C., Yang, M., Ma, B., Jiao, L., Zheng, L., and Huang, K. (2011) Coffee components inhibit amyloid formation of human islet amyloid polypeptide in vitro: possible link between coffee consumption and diabetes mellitus J. Agric. Food Chem. 59, 13147-13155
25. Wang, Q., Yu, X., Li, L., and Zheng, J. Inhibition of amyloid-β aggregation in Alzheimer disease. Curr. Pharm. Des., in press.
26. Kawai, M., Kalaria, R. N., Cras, P., Siedlak, S. L., Velasco, M. E., Shelton, E. R., Chan, H. W., Greenberg, B. D., and Perry, G. (1993) Degeneration of vascular muscle cells in cerebral amyloid angiopathy of Alzheimer disease Brain Res. 623, 142-146
27. Blaise, R., Mateo, V., Rouxel, C., Zaccarini, F., Glorian, M., Béréziat, G., Golubkov, V. S., and Limon, I. (2012) Wild-type amyloid beta 1-40 peptide induces vascular smooth muscle cell death independently from matrix metalloprotease activity Aging Cell 11, 384-393
28. Selkoe, D. J. (2001) Alzheimer's disease: genes, proteins, and therapy Physiol. Rev. 81, 741-766
29. Wang, W., Zheng, L. L., Wang, F., Hu, Z. L., Wu, W. N., Gu, J., and Chen, J. G. (2011) Tanshinone IIA attenuates neuronal damage and the impairment of long-term potentiation induced by hydrogen peroxide J. Ethnopharmacol. 134, 147-155
30. Viegas, C., Jr., Bolzani Vda, S., Barreiro, E. J., and Fraga, C. A. (2005) New anti-Alzheimer drugs from biodiversity: the role of the natural acetylcholinesterase inhibitors Mini-Rev. Med. Chem. 5, 915-926
31. Zhou, L. M., Zuo, Z., and Chow, M. S. S. (2005) Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use J. Clin. Pharmacol. 45, 1345-1359
32. Wang, H., Gao, X., and Zhang, B. (2005) Tanshinone: an inhibitor of proliferation of vascular smooth muscle cells J. Ethnopharmacol. 99, 93-98
33. Wan, A. K., Leung, S. W., Zhu, D. Y., and Man, R. Y. (2008) Vascular effects of different lipophilic components of "Danshen", a traditional Chinese medicine, in the isolated porcine coronary artery J. Nat. Prod. 71, 1825-1828
34. Bi, Y. F., Xu, H. W., Liu, X. Q., Zhang, X. J., Wang, Z. J., and Liu, H. M. (2010) Synthesis and vasodilative activity of tanshinone IIA derivatives Bioorg. Med. Chem. Lett. 20, 4892-4894
35. Gao, Y. G., Song, Y. M., Yang, Y. Y., Liu, W. F., and Tang, J. X. (1979) [Pharmacology of tanshinone (author's transl)] Yao Xue Xue Bao 14, 75-82
36. Shi, L. L., Yang, W. N., Chen, X. L., Zhang, J. S., Yang, P. B., Hu, X. D., Han, H., Qian, Y. H., and Liu, Y. (2012) The protective effects of tanshinone IIA on neurotoxicity induced by beta-amyloid protein through calpain and the p35/Cdk5 pathway in primary cortical neurons Neurochem. Int. 61, 227-235
37. Li, L. X., Dai, J. P., Ru, L. Q., Yin, G. F., and Zhao, B. (2004) Effects of tanshinone on neuropathological changes induced by amyloid beta-peptide(1-40) injection in rat hippocampus Acta Pharmacol. Sin. 25, 861-868
38. Xia, W. J., Yang, M., Fok, T. F., Li, K., Chan, W. Y., Ng, P. C., Ng, H. K., Chik, K. W., Wang, C. C., Gu, G. J., Woo, K. S., and Fung, K. P. (2005) Partial neuroprotective effect of pretreatment with tanshinone IIA on neonatal hypoxia-ischemia brain damage Pediatr. Res. 58, 784-790
39. Chafekar, S. M., Malda, H., Merkx, M., Meijer, E. W., Viertl, D., Lashuel, H. A., Baas, F., and Scheper, W. (2007) Branched KLVFF tetramers strongly potentiate inhibition of beta-amyloid aggregation ChemBioChem 8, 1857-1864
40. Lee, L. L., Ha, H., Chang, Y. T., and DeLisa, M. P. (2009) Discovery of amyloid-beta aggregation inhibitors using an engineered assay for intracellular protein folding and solubility Protein Sci. 18, 277-286
41. Bourhim, M., Kruzel, M., Srikrishnan, T., and Nicotera, T. (2007) Linear quantitation of Abeta aggregation using Thioflavin T: reduction in fibril formation by colostrinin J. Neurosci. Methods 160, 264-268
42. Feng, B. Y., Toyama, B. H., Wille, H., Colby, D. W., Collins, S. R., May, B. C., Prusiner, S. B., Weissman, J., and Shoichet, B. K. (2008) Small-molecule aggregates inhibit amyloid polymerization Nat. Chem. Biol. 4, 197-199
43. Stains, C. I., Mondal, K., and Ghosh, I. (2007) Molecules that target beta-amyloid ChemMedChem 2, 1674-1692
44. Blanchard, B. J., Chen, A., Rozeboom, L. M., Stafford, K. A., Weigele, P., and Ingram, V. M. (2004) Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule Proc. Natl. Acad. Sci. U.S.A. 101, 14326-14332
45. Sood, A., Abid, M., Sauer, C., Hailemichael, S., Foster, M., Torok, B., and Torok, M. (2011) Disassembly of preformed amyloid beta fibrils by small organofluorine molecules Bioorg. Med. Chem. Lett. 21, 2044-2047
46. Gordon, D. J., Sciarretta, K. L., and Meredith, S. C. (2001) Inhibition of beta-amyloid(40) fibrillogenesis and disassembly of beta-amyloid(40) fibrils by short beta-amyloid congeners containing N-methyl amino acids at alternate residues Biochemistry 40, 8237-8245
47. He, C., Hou, Y., Han, Y., and Wang, Y. (2011) Disassembly of amyloid fibrils by premicellar and micellar aggregates of a tetrameric cationic surfactant in aqueous solution Langmuir 27, 4551-4556
48. Li, J., Zhu, M., Manning-Bog, A. B., Di Monte, D. A., and Fink, A. L. (2004) Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease FASEB J. 18, 962-964
49. Price, J. M., Chi, X., Hellermann, G., and Sutton, E. T. (2001) Physiological levels of beta-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production Neurol. Res. 23, 506-512
50. Zheng, J., Ma, B., and Nussinov, R. (2006) Consensus features in amyloid fibrils: sheet-sheet recognition via a (polar or nonpolar) zipper structure Phys. Biol. 3, P1-P4
51. Balbach, J. J., Ishii, Y., Antzutkin, O. N., Leapman, R. D., Rizzo, N. W., Dyda, F., Reed, J., and Tycko, R. (2000) Amyloid fibril formation by Aβ16-22, a seven-residue fragment of the Alzheimer's β-amyloid peptide, and structural characterization by solid state NMR Biochemistry 39, 13748-13759
52. Gazit, E. (2002) A possible role for pi-stacking in the self-assembly of amyloid fibrils FASEB J. 16, 77-83
53. Azriel, R. and Gazit, E. (2001) Analysis of the minimal amyloid-forming fragment of the islet amyloid polypeptide. An experimental support for the key role of the phenylalanine residue in amyloid formation J. Biol. Chem. 276, 34156-34161
54. Claessens, C. G. and Stoddart, J. F. (1997) π-π interactions in self-assembly J. Phys. Org. Chem. 10, 254-272
55. Burley, S. and Petsko, G. (1985) Aromatic-aromatic interaction: a mechanism of protein structure stabilization Science 229, 23-28
56. Tsai, C.-J., Zheng, J., and Nussinov, R. (2006) Designing a nanotube using naturally occurring protein building blocks PLoS Comput. Biol. 2, e42
57. Zheng, J., Ma, B., Chang, Y., and Nussinov, R. (2008) Molecular dynamics simulations of alzheimer's peptide A[beta]40 elongation and lateral association Front. Biosci. 13, 3919-3930
58. Auer, S., Meersman, F., Dobson, C. M., and Vendruscolo, M. (2008) A generic mechanism of emergence of amyloid protofilaments from disordered oligomeric aggregates PLoS Comput. Biol. 4, e1000222
59. Gellermann, G. P., Byrnes, H., Striebinger, A., Ullrich, K., Mueller, R., Hillen, H., and Barghorn, S. (2008) Abeta-globulomers are formed independently of the fibril pathway Neurobiol. Dis. 30, 212-220
60. Zhu, M., Han, S., Zhou, F., Carter, S. A., and Fink, A. L. (2004) Annular oligomeric amyloid intermediates observed by in situ atomic force microscopy J. Biol. Chem. 279, 24452-24459
61. Wang, Q., Shah, N., Zhao, J., Wang, C., Zhao, C., Liu, L., Li, L., Zhou, F., and Zheng, J. (2011) Structural, morphological, and kinetic studies of beta-amyloid peptide aggregation on self-assembled monolayers Phys. Chem. Chem. Phys. 13, 15200-15210
62. Petkova, A. T., Yau, W. M., and Tycko, R. (2006) Experimental constraints on quaternary structure in alzheimer's beta-amyloid fibrils Biochemistry 45, 498-512
63. Paravastu, A. K., Petkova, A. T., and Tycko, R. (2006) Polymorphic fibril formation by residues 10-40 of the alzheimer's {beta}-amyloid peptide Biophys. J. 90, 4618-4629
64. Bitan, G., Kirkitadze, M. D., Lomakin, A., Vollers, S. S., Benedek, G. B., and Teplow, D. B. (2003) Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways Proc. Natl. Acad. Sci. U.S.A. 100, 330-335
65. Urbanc, B., Cruz, L., Yun, S., Buldyrev, S. V., Bitan, G., Teplow, D. B., and Stanley, H. E. (2004) In silico study of amyloid {beta}-protein folding and oligomerization Proc. Natl. Acad. Sci. U.S.A. 101, 17345-17350
66. R. C., Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E., Robb, M. A., Cheeseman, J. R., Montgomery, J. A., Jr., Vreven, T., Kudin, K. N., Burant, J. C., Millam, J. M., Iyengar, S. S., Tomasi, J., Barone, V., Mennucci, B., Cossi, M., Scalmani, G., Rega, N., Petersson, G. A., Nakatsuji, H., Hada, M., Ehara, M., Toyota, K., Fukuda, R., Hasegawa, J., Ishida, M., Nakajima, T., Honda, Y., Kitao, O., Nakai, H., Klene, M., Li, X., Knox, J. E., Hratchian, H. P., Cross, J. B., Bakken, V., Adamo, C., Jaramillo, J., Gomperts, R., Stratmann, R. E., Yazyev, O., Austin, A. J., Cammi, R., Pomelli, C., Ochterski, J. W., Ayala, P. Y., Morokuma, K., Voth, G. A., Salvador, P., Dannenberg, J. J., Zakrzewski, V. G., Dapprich, S., Daniels, A. D., Strain, M. C., Farkas, O., Malick, D. K., Rabuck, A. D., Raghavachari, K., Foresman, J. B., Ortiz, J. V., Cui, Q., Baboul, A. G., Clifford, S., Cioslowski, J., Stefanov, B. B., Liu, G., Liashenko, A., Piskorz, P., Komaromi, I., Martin, R. L., Fox, D. J., Keith, T., Al-Laham, M. A., Peng, C. Y., Nanayakkara, A., Challacombe, M., Gill, P. M. W., Johnson, B., Chen, W., Wong, M. W., Gonzalez, C., and Pople, J. A. (2004) Gaussian 03, Gaussian, Inc., Wallingford, CT.
67. Vanommeslaeghe, K., Hatcher, E., Acharya, C., Kundu, S., Zhong, S., Shim, J., Darian, E., Guvench, O., Lopes, P., Vorobyov, I., and Mackerell, A. D., Jr. (2010) CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields J. Comput. Chem. 31, 671-690
68. Kale, L., Skeel, R., Bhandarkar, M., Brunner, R., Gursoy, A., Krawetz, N., Phillips, J., Shinozaki, A., Varadarajan, K., and Schulten, K. (1999) NAMD2: greater scalability for parallel molecular dynamics J. Comput. Phys. 151, 283-312
69. MacKerell, A. D., Bashford, D., Bellott, M., Dunbrack, R. L., Evanseck, J. D., Field, M. J., Fischer, S., Gao, J., Guo, H., Ha, S., Joseph-McCarthy, D., Kuchnir, L., Kuczera, K., Lau, F. T. K., Mattos, C., Michnick, S., Ngo, T., Nguyen, D. T., Prodhom, B., Reiher, W. E., Roux, B., Schlenkrich, M., Smith, J. C., Stote, R., Straub, J., Watanabe, M., Wiorkiewicz-Kuczera, J., Yin, D., and Karplus, M. (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins J. Phys. Chem. B 102, 3586-3616
70. Lee, M. S., Feig, M., Salsbury, F. R., and Brooks, C. L. (2003) New analytic approximation to the standard molecular volume definition and its application to generalized born calculations J. Comput. Chem. 24, 1348-1356
71. Raha, K. and Merz, K. M., Jr. (2005) Large-scale validation of a quantum mechanics based scoring function: predicting the binding affinity and the binding mode of a diverse set of protein-ligand complexes J. Med. Chem. 48, 4558-4575